Search
Synthetic Conjugated Estrogens, B
go.drugbank.com/drugs/DB09318ApprovedEstrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone … There is currently no generic form of CEEs available as a detailed analytical characterization of the active ingredients or of their estrogenic activity is not available at this time.
Donidalorsen
go.drugbank.com/drugs/DB18751ApprovedInvestigational[L53788] Donidalorsen was approved by the FDA in August 2025 for prophylactic use to prevent HAE attacks.[L53783,L53788] It is the first RNA-targeted therapy approved for HAE.[L53783] … Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of severe swelling induced by excessive production of bradykinin.
Synonyms: -(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL), DNA, D((2'-O-(2-METHOXYETHYL))M5RU-SP-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RA-SP-G-SP-T-SP-M5C-SP-T-SP-M5C-SP-T-SP-T-SP-G-SP-G-SP-M5C-SPHyoscyamine
go.drugbank.com/drugs/DB00424ApprovedInvestigational[L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553] … [A228423] Research into the action of hyoscyamine in published literature dates back to 1826.
Mixtures: UR N-C Urinary AntisepticRavulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigational[A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis. … [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults.
Tapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigational[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDoxercalciferol
go.drugbank.com/drugs/DB06410ApprovedInvestigationalDoxercalciferol is marketed under the brand name Hectoral by Genzyme Corporation, and is manufactured by Catalent Pharma Solutions, Inc. … Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin
Quinidine
go.drugbank.com/drugs/DB00908Approved[A38016] It prolongs cellular action potential by blocking sodium and potassium currents. … A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug.
Cariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigationalCariprazine gained its first global approval in the US in September 2015 [A3941] and was later approved by Health Canada in April 2022. … [L41670] It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N’,N’-dimethylurea hydrochloridePancrelipase protease
go.drugbank.com/drugs/DB11066ApprovedInvestigational[A32742, L2543] The pancrelipase mixture, including pancrelipase protease, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510] … [L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion.
Idoxuridine
go.drugbank.com/drugs/DB00249ApprovedWithdrawnAn analog of deoxyuridine that inhibits viral DNA synthesis. The drug is used as an antiviral agent.